UroGen Pharma Ltd
URGN68
$10.64arrow_drop_down0.56%-$0.06
URGN68
$10.64
arrow_drop_down0.56%Performance History
| Key Stats | |
|---|---|
| Open | $10.65 |
| Prev. Close | $10.71 |
| EPS | -3.02 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 10.53 | 11.05 |
| 52 Week Range | 10.53 | 20.70 |
| Ratios | |
|---|---|
| EPS | -3.02 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About UroGen Pharma Ltd (URGN)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Elizabeth A. Barrett
- Headquarters
- Princeton
- Employees
- 193
- Exchange
- NASDAQ
Keep an eye on UroGen Pharma Ltd
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is UroGen Pharma Ltd's (URGN) price per share?
The current price per share for UroGen Pharma Ltd (URGN) is $10.64. The stock has seen a price change of -$0.06 recently, indicating a -0.56% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for UroGen Pharma Ltd (URGN)?
For UroGen Pharma Ltd (URGN), the 52-week high is $20.7, which is 94.55% from the current price. The 52-week low is $10.54, the current price is 0.97% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is UroGen Pharma Ltd (URGN) a growth stock?
UroGen Pharma Ltd (URGN) has shown an average price growth of -4.97% over the past three years. It has received a score of 69 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying UroGen Pharma Ltd as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is UroGen Pharma Ltd (URGN) stock price performance year to date (YTD)?
As of the latest data, UroGen Pharma Ltd (URGN) has a year-to-date price change of -30.05%. Over the past month, the stock has experienced a price change of -7.88%. Over the last three months, the change has been -17.96%. Over the past six months, the figure is -35.55%. Looking at a longer horizon, the five-year price change stands at -68.85%.
help
Is UroGen Pharma Ltd (URGN) a profitable company?
UroGen Pharma Ltd (URGN) has a net income of -$102.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.68% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -69.61% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $82.71M, with a revenue growth rate of 28.52%, providing insight into the company's sales performance and growth. The gross profit is $73.35M. Operating income is noted at -$65.54M. Furthermore, the EBITDA is -$83.28M.
help
What is the market capitalization of UroGen Pharma Ltd (URGN)?
UroGen Pharma Ltd (URGN) has a market capitalization of $449M. The average daily trading volume is 10.65, indicating the stock's liquidity and investor engagement.